The university of Texas MD Anderson Cancer Center Houston, TX 77030
Oncology
Aman U. Buzdar, MB
|
|
Give Review
Aman U. Buzdar, MB is an expert in the field of Oncology. He went to Nishtar Medical College. He over the years received 5 awards: "America's Top Doctors", "Top Doctors:SE Texas", "America's Top Doctors for Cancer", "Redbook Magazine: Top Breast Cancer Doctors" and "Super Doctor". Aman Buzdar has written publications. He has 100 publications published with PubMed. The lastest paper is: 'Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.' He is registered with Medicare and accepts Medicare payments.
Publications
- Identification of early Breast cancer patient cohorts who may benefit from lapatinib therapy.
- Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HE...
- Locoregional Recurrence Risk for Patients With T1,2 Breast Cancer With 1-3 Positive Lymph Nodes Treated With Mastectomy and Systemic Treatment.
- Which threshold for ER positivity? A retrospective study based on 9639 patients.
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab ...
- Combination endocrine treatments unproven in Breast cancer.
- TSPYL5 SNPs: Association with Plasma Estradiol Concentrations and Aromatase Expression.
- Mammographic Breast density response to aromatase inhibition.
- Adjuvant lapatinib for women with early-stage HER2-positive Breast cancer: a randomised, controlled, phase 3 trial.
- Randomized double-blind phase 2 trial of 3 doses of TAS-108 in patients with advanced or metastatic postmenopausal Breast cancer.
- Screening for Cardiac Risk Before Anthracycline Administration: What Are The Real Benefits?
- Short -term biomarker modulation prevention study of Anastrozole in Women at increased risk for second primary Breast cancer.
- Novel Staging System for Predicting Disease-Specific Survival in Patients With Breast Cancer Treated With Surgery As the First Intervention: Time to Modify the Current...
- Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced Breast cancer: long-term results.
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison W...
- Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive Breast cancer.
- Predictive algorithms for adjuvant therapy: TransATAC.
- Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable Breast cancer: impac...
- Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.
- Classification of ipsilateral Breast tumor recurrences after Breast conservation therapy can predict patient prognosis and facilitate treatment planning.
- Usage of erythropoiesis-stimulating agents in cancer patients at an academic cancer center and experience with specific care management tools for Anemia.
- Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the Breast.
- Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.
- Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive Breast...
- Variation in anastrozole metabolism and pharmacodynamics in women with early Breast cancer.
- A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic Breast cancer.
- A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced Breast cancer.
- Prognosis of women with metastatic Breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
- Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes.
- Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive Breast cancer.
- Hormone receptor status and pathologic response of HER2-positive Breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
- Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary Breast cancer.
- Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV Breast cancer.
- Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable Breast cancer.
- Residual risk of Breast cancer recurrence 5 years after adjuvant therapy.
- Staging of Breast cancer in the neoadjuvant setting.
- Clinical experience with epothilones in patients with Breast cancer.
- Preoperative therapy in invasive Breast cancer: pathologic assessment and systemic therapy issues in operable disease.
- Summary of aromatase inhibitor clinical trials in postmenopausal women with early Breast cancer.
- Endocrine and targeted manipulation of Breast cancer: summary statement for the Sixth Cambridge Conference.
- Combined use of clinical and pathologic staging variables to define outcomes for Breast cancer patients treated with neoadjuvant therapy.
- Recent advances in the hormonal treatment of Breast cancer.
- Preoperative chemotherapy treatment of Breast cancer--a review.
- Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic Breast cancer.
- Measurement of residual Breast cancer burden to predict survival after neoadjuvant chemotherapy.
- Inflammatory Breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease.
- Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience.
- Trends for inflammatory Breast cancer: is survival improving?
- Letrozole compared with tamoxifen as initial adjuvant therapy for Breast cancer.
- Adjuvant chemotherapy for high-risk operable Breast cancer.
- Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary Breast cancer after initiation of primary chemotherapy.
- Novel clinical trial designs for treatment of ductal carcinoma in situ of the Breast with trastuzumab (herceptin).
- Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth fact...
- Accuracy of the combination of mammography and sonography in predicting tumor response in Breast cancer patients after neoadjuvant chemotherapy.
- The safety of Breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy.
- Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in Breast cancer.
- Fulvestrant: pharmacologic profile versus existing endocrine agents for the treatment of Breast cancer.
- Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for Breast c...
- Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mast...
- Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in Breast cancer.
- Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary Breast carcinoma: follow-up at 12 years.
- Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive Breast cancer: the Pre-Operative "Arimid...
- Update on the management of inflammatory Breast cancer.
- Letrozole or tamoxifen in early Breast cancer.
- Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory Breast carcinoma axillary lymph node metastases afte...
- Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
- Dietary modification and risk of Breast cancer.
- Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
- Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with Breast cancer: emerging data.
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
- Distribution of (7alpha)-21-[4-[(diethylamino) methyl]-2-methoxyphenoxy]-7-methyl-19-norpregna-1,3,5(10)-trien-3-ol-20-[14C]2-hydroxy-1,2,3-propanetricarboxylate ([14C...
- Outcome after pathologic complete eradication of cytologically proven Breast cancer axillary node metastases following primary chemotherapy.
- Adjuvant systemic therapy for male Breast carcinoma.
- Optimum use of aromatase inhibitors in the adjuvant treatment of early Breast cancer.
- Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for Breast cancer.
- Factors predictive of distant metastases in patients with Breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
- Combined-modality treatment for isolated recurrences of Breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and a...
- Weekly paclitaxel improves pathologic complete remission in operable Breast cancer when compared with paclitaxel once every 3 weeks.
- The natural history of Breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstituti...
- Women age < or = 35 years with primary Breast carcinoma: disease features at presentation.
- Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized tr...
- Predictors of locoregional recurrence in patients with locally advanced Breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
- Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
- TAS-108: a novel steroidal antiestrogen.
- Invasive lobular Carcinoma classic type: response to primary chemotherapy and survival outcomes.
- TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotro...
- Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced Breast cancer treated with neoadjuvant chemotherapy a...
- Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in Breast cancer patients.
- Central nervous system metastases in patients with high-risk Breast carcinoma after multimodality treatment.
- Colitis in patients with Breast carcinoma treated with taxane-based chemotherapy.
- The role of aromatase inhibitors in the adjuvant treatment of Breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
- p53 expression as a prognostic marker in inflammatory Breast cancer.
- The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
- Current developments in hormonal therapy of Breast cancer.
- Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory Breast carcinoma.
- 'Chemobrain' in Breast carcinoma?: a prologue.
- Phase III study of letrozole versus tamoxifen as first-line therapy of advanced Breast cancer in postmenopausal women: analysis of survival and update of efficacy from...
- Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radio...
- Lack of association between amplification of her-2 and response to preoperative taxanes in patients with Breast carcinoma.
Schools
Bahuddin Zakaria University Nishtar Medical College
Kuakini Hospital
Lakewood Hospital
Norwalk Hospital
Conditions Treated
- Acute Leukemia
- Anemia
- Breast Cancer
- Carcinoma in Situ
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:SE Texas
- America's Top Doctors for Cancer
- Redbook Magazine: Top Breast Cancer Doctors
- Super Doctor
Education
-
University of Texas MD Anderson Cancer Center -
Case Western Reserve University - MetroHealth -
Nishtar Medical College
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1568568749 | |
| NPPES Provider LastName | BUZDAR | |
| NPPES Provider FirstName | AMAN | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 75.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1568568749 |
| Last Name Of The Provider | BUZDAR |
| First Name Of The Provider | AMAN |
| View All |
Similar Doctors
|
|
Dr. William G. Wierda, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frank V. Fossella, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Overman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert C. Bast Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aihua E. Yen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paulo M. Hoff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Teresa G. Hayes, MD |
|
|
Dr. Jennifer K. Litton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Faye M. Johnson, MD
This Doctor is OpenDoctor Recommended.
|